Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Head-to-head trial data show Wegovy produces roughly 2.5 times the weight loss of liraglutide
Tirzepatide has the longest real-world tolerability data among dual agonists
Results Training data We used experimental potency measurements (EC 50 ) at both GCGR and GLP-1R for a total of 125 peptide variants to fit models that relate peptide sequences to in vitro activity against each receptor
PubMed laboratory research record [PMID: 39148685] PubMed record related to this compound for laboratory literature review
The trial found that after 5 years, Wegovy significantly reduced the risk of death from heart disease by 15% and reduced the risk of cardiovascular events including nonfatal heart attacks and strokes by 20%, compared to an inactive placebo
US$ 27.57
US$ 27.81
US$ 22.49
US$ 27.07
US$ 22.81
US$ 29.78
US$ 28.82
US$ 20.26
US$ 21.95
US$ 23.31
